Impact of Forearm Immobilization on Muscle Metabolism in Type 2 Diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how short-term immobilization of the forearm affects muscle glucose uptake and amino acid balance in individuals with Type 2 Diabetes (T2D) compared to healthy individuals. Participants will undergo two days of forearm immobilization, simulating local physical inactivity. Measurements of arteriovenous forearm balance will be taken alongside stable isotope tracer infusion to assess metabolic changes before, during, and after the immobilization period.

Why it matters

Who can join: the full rules

Inclusion criteria

* Males and females with or without diagnosed type 2 diabetes
* Use lifestyle changes, metformin, gliclazide, or a combination thereof as oral glucose-lowering treatments for T2D
* Aged 18-80 years at the time of signing informed consent
* 18.5 ≥ BMI ≤ 35 kg·m2

Exclusion criteria

* Type 1 or a genetic form of diabetes
* Any diagnosed cardiovascular (heart) disease or high blood pressure (≥160 mmHg systolic and/or ≥100 mmHg diastolic)
* Chronic use of any prescribed or over-the-counter pharmaceuticals (excluding oral contraceptives and contraceptive devices) that interact with muscle substrate metabolism (e.g. selective serotonin reuptake inhibitors)
* Consumption of a low-carbohydrate diet
* Smoking or chewing tobacco
* Known anaemia
* Regular use of dietary protein and/or amino acid supplements (\>3 times per week)
* Currently involved in a structured progressive resistance training program (\>3 times per week)
* A personal or family history of thrombosis (clots)
* Any previous motor disorders or inborn errors in muscle and/or lipid metabolism
* History of kidney disease
* History of liver disease
* Pregnant or breastfeeding
* History of any drug or alcohol abuse in the past two years
* Claustrophobia
* Unable to give consent

Where it's running

• Wageningen University and Research
  Wageningen, Gelderland, Netherlands Recruiting

Study contacts

• Study coordinator: Marlou Dirks, PhD
• Email: marlou.dirks@wur.nl
• Phone: +31 317 480 100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acute Blood Flow Restriction Walking in Type 2 Diabetes

  This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.

  Recruiting University of British Columbia · Kelowna, British Columbia · NCT07928531

• Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin

  This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.

  Recruiting Medical University of Bialystok · Bialystok · NCT07919236

• Differentiating heart disease in autoimmune vs. type 2 diabetes

  This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.

  Recruiting University of Roma La Sapienza · Rome, Roma · NCT07911007

• Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses

  This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.

  Recruiting at 2 sites German Institute of Human Nutrition · Berlin and 1 other locations · NCT07888257

• Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar

  This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.

  Recruiting German Institute of Human Nutrition · Potsdam, Potsdam-Rehbrücke · NCT07868601

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.